Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yield10 Bioscience was an agricultural biosciences company focused on developing advanced genetic traits in the oilseed crop Camelina sativa using its proprietary Trait Factory™ platform. The company's main innovations included engineering Camelina to produce biodegradable PHA bioplastics directly in seeds—targeting markets such as sustainable plastics replacement and water treatment—and developing high-yielding or specialty-oil varieties for use in food ingredients and low-carbon biofuels. The company also licensed its yield-improving genetic traits to major seed companies for deployment into row crops like corn and soybean. In December 2024 it filed for Chapter 11 bankruptcy protection due to financial difficulties.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yield10 Bioscience.